Biocept Inc (NASDAQ:BIOC) shares saw strong trading volume on Thursday . 46,706,071 shares were traded during mid-day trading, an increase of 350% from the previous session’s volume of 10,369,934 shares.The stock last traded at $0.36 and had previously closed at $0.29.
Separately, Maxim Group reissued a “buy” rating and issued a $1.00 target price on shares of Biocept in a research note on Friday, March 6th.
The stock has a market cap of $30.33 million, a PE ratio of -0.25 and a beta of 0.08. The stock has a fifty day simple moving average of $0.35 and a two-hundred day simple moving average of $0.47. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.36 and a current ratio of 2.50.
A hedge fund recently bought a new stake in Biocept stock. Renaissance Technologies LLC bought a new stake in shares of Biocept Inc (NASDAQ:BIOC) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 457,744 shares of the medical research company’s stock, valued at approximately $131,000. Renaissance Technologies LLC owned about 0.96% of Biocept at the end of the most recent quarter. Institutional investors own 1.11% of the company’s stock.
About Biocept (NASDAQ:BIOC)
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
Featured Article: How Important is Technical Analysis of Stocks
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.